Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Longqi Jiangzhi decoction is a traditional Chinese medicine (TCM) herbal formula developed by the Shanghai Municipal Hospital of Traditional Chinese Medicine for the treatment of non-alcoholic fatty liver disease (NAFLD). The decoction is a multi-ingredient formulation consisting of *Gentiana scabra* (5g), *Astragalus membranaceus* (10g), *Rhizoma Alismatis* (10g), *Crataegus pinnatifida* (10g), and *Citri Reticulatae Pericarpium* (5g). It is currently being evaluated in Phase 2 clinical trials to assess its efficacy in reducing hepatic steatosis and improving clinical symptoms in adult patients. The therapeutic effect is likely derived from the synergistic metabolic and hepatoprotective properties of its constituent herbs, which are traditionally used to clear heat, resolve dampness, and invigorate blood.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Longqi Jiangzhi decoction.